CoreRx™ celebrates its first year of operations August 1, 2007.  In their initial year of business CoreRx™ has serviced more than 25 clients, both domestic and abroad.  The company has positioned themselves for successful growth strategies over the next few years.  Included in CoreRx’s™ growth strategy is the collaborative agreement between CoreRx™ and JRS Pharma, one of the world’s leading excipient manufacturers, to stabilize drug molecules using JRS’ patented PROSOLV® technology.  Also, included in CoreRx’s™ growth strategy, is the company’s strict dedication to continually increase capital expenditures for equipment procurement in order to keep current and future clients on track for their respective goals and timelines.   (more…)